BR0107618A - Pró-medicamentos solúveis em água de compostos de azol - Google Patents

Pró-medicamentos solúveis em água de compostos de azol

Info

Publication number
BR0107618A
BR0107618A BR0107618-3A BR0107618A BR0107618A BR 0107618 A BR0107618 A BR 0107618A BR 0107618 A BR0107618 A BR 0107618A BR 0107618 A BR0107618 A BR 0107618A
Authority
BR
Brazil
Prior art keywords
water
soluble
azole compounds
compounds
soluble prodrugs
Prior art date
Application number
BR0107618-3A
Other languages
English (en)
Inventor
Yasutsugu Ueda
John D Matiskella
Jerzy Golik
Thomas W Hudyma
Chung-Pin Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR0107618A publication Critical patent/BR0107618A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • C07F9/6518—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polymerization Catalysts (AREA)

Abstract

"PRó-MEDICAMENTOS SOLúVEIS EM áGUA DE COMPOSTOS DE AZOL". São fornecidos pró-medicamentos solúveis em água de compostos antifúgicos tiazol com um grupo hidroxi secundário ou terciário. Mais particularmente, são fornecidos novos compostos antifúngicos tiazol solúveis em água com a fórmula geral em que A é a parte não-hidroxi de um composto antifúngico triazol do tipo que tem um grupo hidroxila secundário ou terciária e R e R^ 1^ são bem definidos na especificação.
BR0107618-3A 2000-01-20 2001-01-16 Pró-medicamentos solúveis em água de compostos de azol BR0107618A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17716900P 2000-01-20 2000-01-20
US24996900P 2000-11-20 2000-11-20
PCT/US2001/001284 WO2001052852A1 (en) 2000-01-20 2001-01-16 Water soluble prodrugs of azole compounds

Publications (1)

Publication Number Publication Date
BR0107618A true BR0107618A (pt) 2002-11-12

Family

ID=26873001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107618-3A BR0107618A (pt) 2000-01-20 2001-01-16 Pró-medicamentos solúveis em água de compostos de azol

Country Status (22)

Country Link
US (1) US6362172B2 (pt)
EP (1) EP1284737B1 (pt)
JP (1) JP3766804B2 (pt)
KR (1) KR100748299B1 (pt)
CN (1) CN1178665C (pt)
AT (1) ATE300946T1 (pt)
AU (1) AU782177C (pt)
BR (1) BR0107618A (pt)
CA (1) CA2397734C (pt)
CZ (1) CZ20022822A3 (pt)
DE (1) DE60112433T2 (pt)
DK (1) DK1284737T5 (pt)
ES (1) ES2247131T3 (pt)
HU (1) HU229226B1 (pt)
IL (2) IL150798A0 (pt)
MX (1) MXPA02007120A (pt)
NO (1) NO330352B1 (pt)
NZ (1) NZ519354A (pt)
PL (1) PL206024B1 (pt)
PT (1) PT1284737E (pt)
RU (1) RU2266909C2 (pt)
WO (1) WO2001052852A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP4801096B2 (ja) 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
JO2691B1 (en) 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
JP5046959B2 (ja) * 2005-12-20 2012-10-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 水溶性アゾールプロドラッグの製造方法
WO2007092580A2 (en) * 2006-02-08 2007-08-16 Phibro-Tech Inc. Biocidal azole emulsion concentrates having high active ingredient content
ES2351365T3 (es) 2006-02-22 2011-02-03 EISAI R&D MANAGEMENT CO., LTD. Composición farmacéutica estabilizada.
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
KR101677126B1 (ko) 2008-05-20 2016-11-22 노이로제스엑스, 인코포레이티드 탄산염 프로드러그 및 그것의 사용 방법
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
US20130288956A1 (en) 2010-11-05 2013-10-31 Eisai R&D Management Co., Ltd. Combined pharmaceutical composition as antifungal agent
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
RU2618456C2 (ru) * 2010-12-16 2017-05-03 Плэтформ Брайтворкс Ту, Лтд Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
EP2723452A2 (en) 2011-06-22 2014-04-30 Vyome Biosciences Pvt Ltd Conjugate-based antifungal and antibacterial prodrugs
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
EA026209B1 (ru) 2012-01-20 2017-03-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
TWI574705B (zh) * 2012-04-20 2017-03-21 衛材Ｒ＆Ｄ企管股份有限公司 Capsules
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20160128944A1 (en) 2013-06-04 2016-05-12 Vyome Biosciences Pvt. Ltd. Coated particles and compositions comprising same
MX394441B (es) 2014-01-29 2025-03-24 Vyome Therapeutics Ltd Una formulación a base de besifloxacina para usarse en el tratamiento del acné resistente a fármacos
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN104926870B (zh) * 2014-03-21 2017-02-08 合肥久诺医药科技有限公司 一种福司氟康唑的精制方法
US9725473B2 (en) * 2015-07-28 2017-08-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN107501255B (zh) * 2017-09-12 2019-08-23 成都施贝康生物医药科技有限公司 一种艾沙康唑衍生物及其用途
CN108676031A (zh) * 2018-05-29 2018-10-19 重庆威鹏药业有限公司 水溶性三唑类抗真菌膦酸化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
CA2111527C (en) 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives
CA2129288C (en) 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
US5714490A (en) * 1993-12-21 1998-02-03 Schering Corporation Tetrahydrofuran antifungals
PL181193B1 (pl) 1993-12-21 2001-06-29 Schering Corp Nowe pochodne tetrahydrofuranowe o działaniu przeciwgrzybicznym, kompozycja farmaceutyczna do leczenia infekcji grzybiczych oraz sposób wytwarzania tych związków
NZ278882A (en) 1994-01-24 1997-06-24 Janssen Pharmaceutica Nv Piperazine-containing azole antifungal compounds
NZ270418A (en) 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
SK27097A3 (en) 1995-06-02 1997-09-10 Schering Corp Tetrahydrofuran antifungals
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
EP0829478A3 (en) 1996-09-09 1998-03-25 F. Hoffmann-La Roche Ag N-Benzylimidazolium and N-benzyltriazolium derivatives, their preparation and their use as antifungal and antimycotic agents
PT1056754E (pt) 1998-01-29 2004-03-31 Bristol Myers Squibb Co Derivados fosfatados de 1,3,4-oxadiazolona de diarilo
US5883097A (en) 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU1915500A (en) * 1998-11-20 2000-06-13 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Also Published As

Publication number Publication date
DK1284737T3 (da) 2005-11-28
EP1284737B1 (en) 2005-08-03
AU782177C (en) 2007-10-18
DE60112433D1 (de) 2005-09-08
ES2247131T3 (es) 2006-03-01
HU229226B1 (en) 2013-09-30
US20010041691A1 (en) 2001-11-15
NO330352B1 (no) 2011-04-04
HUP0204405A3 (en) 2005-02-28
DE60112433T2 (de) 2006-05-18
DK1284737T5 (da) 2007-09-24
IL150798A (en) 2006-08-01
JP3766804B2 (ja) 2006-04-19
CN1395485A (zh) 2003-02-05
AU782177B2 (en) 2005-07-07
JP2003520235A (ja) 2003-07-02
US6362172B2 (en) 2002-03-26
WO2001052852A1 (en) 2001-07-26
ATE300946T1 (de) 2005-08-15
IL150798A0 (en) 2003-02-12
PL356164A1 (en) 2004-06-14
NO20023468L (no) 2002-07-29
CA2397734A1 (en) 2001-07-26
PT1284737E (pt) 2005-11-30
CA2397734C (en) 2010-08-17
EP1284737A1 (en) 2003-02-26
RU2266909C2 (ru) 2005-12-27
EP1284737A4 (en) 2003-03-19
CN1178665C (zh) 2004-12-08
NZ519354A (en) 2004-05-28
NO20023468D0 (no) 2002-07-19
MXPA02007120A (es) 2003-01-28
AU2948501A (en) 2001-07-31
KR100748299B1 (ko) 2007-08-09
PL206024B1 (pl) 2010-06-30
KR20020070492A (ko) 2002-09-09
HUP0204405A2 (en) 2003-05-28
CZ20022822A3 (cs) 2003-02-12

Similar Documents

Publication Publication Date Title
PT1284737E (pt) Pro-farmacos de compostos de azole soluveis em agua
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
AU7278500A (en) Fungicides
BRPI0402451A (pt) Compostos colorantes
ATE368049T1 (de) Nukleotidderivate mit einer reportergruppe und einer polymerase-enzym-blockierende gruppe
GB0007405D0 (en) Compounds
BR9801122A (pt) Fecho rápido para a montagem de um cilindro de meio de pressão em uma caixa
EP0945764A3 (en) Photoresist composition
WO2002094020A8 (de) Verwendung von triazolopyrimidin-derivaten als mikrobizide im materialschutz
BR0115448A (pt) Processo para compostos azóis solúveis em água
WO1998002149A3 (en) Use of idebenone and analogues against beta amyloid induced cytotoxicity
MY128164A (en) Compounds
WO2003039446A3 (fr) Derives de 2-amino-4-pyridylmethyl-thiazoline et leur utilisation comme inhibiteurs de no-synthase inductible
WO2002038277A3 (de) Sammler für die aufbereitung von nicht-eisen-metallsulfiden
CA2355533A1 (en) Colorant compounds, phase change ink compositions and methods of printing
TR200001819T2 (tr) COPD tedavi yöntemi.
JO2691B1 (en) Monolysine salts for azole compounds
DE60106956D1 (de) 4-cyklohexyl-1,3,2-oxazaborolidine als chirale hilfsmittel
WO2001079268A3 (en) A glycopeptide and preparation thereof
ATE206125T1 (de) Furoindolizine
BRPI0407191A (pt) Módulo de instalação
BR0210201A (pt) Composição
BG102578A (en) 1,3-oxazin-4-on derivatives as herbicides
WO2002051822A3 (en) Isothiazolecarboxamides as microbicides
WO2002033216A3 (en) Corrosion inhibitor-drag reducer combinations

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: EISAI CO., LTD. (JP)

Free format text: TRANSFERIDO DE: BRISTOL-MYERS SQUIBB COMPANY

B25A Requested transfer of rights approved

Owner name: EISAI RANDD MANAGEMENT CO., LTD. (JP)

Free format text: TRANSFERIDO DE: EISAI CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]